Stone JH, Wallace Z, Perugino CA, et al. Final Results of an Open Label Phase 2 Study of a Reversible B Cell Inhibitor, Xmab®5871, in IgG4-Related Disease. ACR 2017, abstract 4L.
Toepassing eHealth bij medicatiegebruik reuma
mrt 2023 | Arthritis psoriatica, Jicht, RA, Spondyloartritis